This study is designed to treat HIV-infected patients with Burkitt's lymphoma or atypical Burkitt's with a modified version of the R-CODOX-M/IVAC regimen which is standard treatment for people with Burkitt's and atypical Burkitt's lymphoma. Study duration will be one year.

Inclusion Criteria:

• Men and women 18 years or older
• Documented HIV infection
• Laboratory tests within acceptable ranges for study inclusion.

Exclusion criteria:

• Any lymphoma other than Burkitt's or atypical Burkitt's lymphoma
• Known pregnancy or breast feeding
• Medical illness unrelated to lymphoma that may prevent the administration of chemotherapy safely
• History of any other malignancy ithing the past 5 years other than basal or squamous cell carcinoma and carcinoma in situ of the cervix or cutaneous Kaposi's sarcoma

This study is being conducted by Dr. Ronald Mitsuyasu under IRB #06-10-095-01

If you think you might be interested in participating in this study, please contact Blanca Corea at 310-557-9062 or email at bcorea@mednet.ucla.edu

Return to Clinical Trials main page